ClinicalTrials.gg
Active, not recruitingNCT06497504B-FocusUpdated Nov 6, 2026

Study of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection (B-Focus)

A Phase 2 interventional study of Bepirovirsen and Placebo in Hepatitis B, sponsored by GlaxoSmithKline. Active, not recruiting at 51 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
153
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing bepirovirsen in Hepatitis B — 3 open to participants now, 6 under way, none of them phase 3. bepirovirsen · Hepatitis B.

Enrollment
7th of 16
153 · median 103
Started
2024
with 1 other
Phase 2
7 of 16
1 open now
Registered
12th of 16
by date
Lead sponsor
15 of 16
GlaxoSmithKline

Among the 16 studies testing bepirovirsen in Hepatitis B, this one is the 7th largest by enrollment, is one of 2 that started in 2024, is one of 7 in phase 2, and was the 12th registered.

Hepatitis B

1,046 studies on the registry are indexed under Hepatitis B; 139 are open to participants now.

Browse Hepatitis B studies →

Open to participants now

3 of the 16 studies testing bepirovirsen in Hepatitis B are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About bepirovirsen

bepirovirsen: first FDA approval 2026 (HIBSAGO). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 80 Hepatitis B studies recruiting now, 40 (50%) set no upper age limit and 35 (44%) stop at 75 or younger; 14 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing bepirovirsen in Hepatitis B, or all of them as a file.
02

Study summary

This study will evaluate the efficacy and safety of bepirovirsen compared to placebo in participants with human immunodeficiency virus (HIV)/hepatitis B virus (HBV) co-infection.

03

Conditions studied

  • Hepatitis B

Keywords

  • Antiretroviral treatment
  • Bepirovirsen
  • Human immunodeficiency virus
  • Hepatitis B virus
  • Placebo
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Documented chronic virus (HBV) infection and documented (HIV)-1 infection greater than equal to (>=) 12 months prior to Screening.
  2. Must be on uninterrupted antiretroviral therapy (ART) containing at least tenofovir disoproxil (TDF) or tenofovir alafenamide (TAF) plus lamivudine (3TC) or emtricitabine (FTC) for greater than (>)12 months, with no planned changes to the stable regimen over the duration of the study.

    o Switch in ART is permitted >=6 months prior to Screening for reasons not related to loss of HIV or HBV control (e.g., change in formulary, tolerability, side effects).

  3. Documented evidence of at least 2 plasma HIV-1 ribonucleic acid (RNA) measurements less than (\<) 50 copies per milliliter (copies/mL) are required in the 12 months prior to Screening: 1 within 6 to 12 months prior to Screening and 1 within 6 months prior to Screening.
  4. Plasma or serum HBV deoxyribonucleic acid (DNA) concentration must be adequately suppressed, defined as plasma or serum HBV DNA \<90 international units per milliliter (IU/mL).
  5. Plasma or serum HBsAg concentration >100 IU/mL and \<=3000 IU/mL.
  6. Plasma HIV-1 RNA concentration must be undetectable, defined as plasma HIV 1 RNA \<50 copies/mL.
  7. Cluster of differentiation 4 (CD4) count >=350 cells per cubic millimeter (cells/mm\^3).
  8. (ALT) \<=2 times (ULN).

Exclusion criteria

Exclusion Criteria:

  1. History of or suspected liver cirrhosis and/or evidence of cirrhosis.
  2. Diagnosed or suspected hepatocellular carcinoma (HCC).
  3. History of extrahepatic disorders possibly related to immune conditions (e.g., nephrotic syndrome, any type of glomerulonephritis, polyarteritis nodosa, cryoglobulinemia, uncontrolled hypertension).
  4. Coinfection with:

    1. virus (HCV) with positive HCV antibody and detectable HCV RNA at Screening.

      I. HCV treatment should have completed >12 months prior to Screening.

    2. Hepatitis D virus (HDV) defined as positive or equivocal HDV antibody regardless of HDV RNA level.
  5. abnormalities, aside from -1 infection and chronic HBV infection in medical history (e.g., moderate severe liver disease other than chronic HBV/HIV, acute coronary syndrome within 6 months of Screening, major surgery within 3 months of Screening, significant/unstable cardiac disease, uncontrolled diabetes, bleeding diathesis coagulopathy) or clinically significant physical examination findings.
  6. Untreated syphilis infection (positive rapid plasma reagin [RPR] at Screening without clear documentation of treatment) are excluded unless they complete treatment during the Screening period and 7 days prior to randomization.
  7. History of within the past 5 years with the exception of specific cancers that are cured by surgical resection (e.g., skin cancer). Participants under evaluation for possible malignancy are not eligible.
  8. History of vasculitis or presence of symptoms and signs of potential vasculitis (e.g., vasculitic rash, skin ulceration, repeated blood detected in urine without identified cause), current or history of an condition or history/presence of other diseases that may be associated with vasculitis condition (e.g., systemic lupus erythematosus, rheumatoid arthritis, relapsing polychondritis, mononeuritis multiplex).
  9. Participants who in the investigator's judgment, have a significant risk of suicide or self-harm.
  10. Alcohol or drug abuse/dependence
  11. Currently taking, or took within 3 months of Screening, any drugs (e.g., prednisone), other than a short course of therapy (\<=2 weeks) or topical/inhaled use.
  12. Participants to whom immunosuppressive treatment, including therapeutic doses of steroids, is should not be considered for enrolment in the study.
  13. Currently taking, or has taken within 12 months of Screening, any interferon containing therapy.
  14. Participants requiring anti coagulation therapies (e.g., warfarin, Factor Xa inhibitors) or anti agents (including but not limited to clopidogrel or aspirin) unless treatment can safely be discontinued throughout duration of study intervention, by the discretion of the investigator. Occasional use is permitted.
  15. Treatment with an HIV-1 immunotherapeutic vaccine within 90 days of Screening.
  16. Prior treatment with any oligonucleotide or small interfering ribonucleic acid (siRNA) within 12 months prior to the first dosing day.
  17. Prior treatment with bepirovirsen.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
153 participants (actual)

Study arms

  • Experimental
    Participants receiving Bepirovirsen

    Participants will receive bepirovirsen.

    Drug: Bepirovirsen

  • Placebo comparator
    Participants receiving Placebo

    Participants will receive placebo.

    Drug: Placebo

Interventions

  • Bepirovirsen will be administered.

  • DrugPlacebo

    Placebo will be administered.

06

What researchers measure

Primary outcomes

  1. Percentage of participants achieving hepatitis B virus (HBV) virologic response at 36 weeks after scheduled end of study treatment in absence of rescue medication

    HBV virologic response defined as HBV surface antigen (HBsAg) not detected and HBV deoxyribonucleic acid (DNA) less than (\<) lower limit of quantification (LLOQ).

    Time frame: At study week 60

Secondary outcomes

  1. Percentage of participants achieving HBV virologic response at the scheduled end of study treatment in absence of rescue medication

    HBV virologic response defined as HBsAg not detected and HBV DNA \<LLOQ.

    Time frame: At study week 24

07

Study locations

51 sites
  • GSK Investigational Site
    Bakersfield, California 93301, United States
  • GSK Investigational Site
    San Francisco, California 94115, United States
  • GSK Investigational Site
    Orlando, Florida 32803-1851, United States
  • GSK Investigational Site
    West Palm Beach, Florida 33409, United States
  • GSK Investigational Site
    Baltimore, Maryland 21287, United States
  • GSK Investigational Site
    Minneapolis, Minnesota 55415, United States
  • GSK Investigational Site
    Hillsborough, New Jersey 08844, United States
  • GSK Investigational Site
    Almagro, C1427CEA, Argentina
  • GSK Investigational Site
    Buenos Aires, 1023, Argentina
  • GSK Investigational Site
    Buenos Aires, C1181ACI, Argentina
  • GSK Investigational Site
    Buenos Aires, C1425AGC, Argentina
  • GSK Investigational Site
    La Plata, B1900AVG, Argentina
  • GSK Investigational Site
    Rosario, S2002KDR, Argentina
  • GSK Investigational Site
    Aracaju, 49060-010, Brazil
  • GSK Investigational Site
    Campinas, 13034-685, Brazil
  • GSK Investigational Site
    Curitiba, 80810-050, Brazil
  • GSK Investigational Site
    Manaus, 69040-000, Brazil
  • GSK Investigational Site
    Salvador, 40110-060, Brazil
  • GSK Investigational Site
    São Paulo, 04121-000, Brazil
  • GSK Investigational Site
    Ottawa, Ontario K1H 8L6, Canada
  • GSK Investigational Site
    Toronto, Ontario M5G 1K2, Canada
  • GSK Investigational Site
    Montreal, Quebec H2L 4P9, Canada
  • GSK Investigational Site
    Montreal, Quebec H4A 3J1, Canada
  • GSK Investigational Site
    Québec, Quebec G1V 4G2, Canada
  • GSK Investigational Site
    Marseille, 13003, France
  • GSK Investigational Site
    Melun, 77000, France
  • GSK Investigational Site
    Montpellier, 34295, France
  • GSK Investigational Site
    Nantes, 44093, France
  • GSK Investigational Site
    Paris, 75012, France
  • GSK Investigational Site
    Paris, 75018, France
  • GSK Investigational Site
    Genova, 16132, Italy
  • GSK Investigational Site
    Milan, 20157, Italy
  • GSK Investigational Site
    Milan, 20162, Italy
  • GSK Investigational Site
    Naples, 80131, Italy
  • GSK Investigational Site
    Roma, 00153, Italy
  • GSK Investigational Site
    Sassari, 07100, Italy
  • GSK Investigational Site
    Durban, KwaZulu-Natal 4052, South Africa
  • GSK Investigational Site
    Ekurhuleni, 1459, South Africa
  • GSK Investigational Site
    Johannesburg, 2092, South Africa
  • GSK Investigational Site
    Barcelona, 08036, Spain
  • GSK Investigational Site
    Córdoba, 14004, Spain
  • GSK Investigational Site
    Madrid, 28031, Spain
  • GSK Investigational Site
    Madrid, 28040, Spain
  • GSK Investigational Site
    Madrid, 28041, Spain
  • GSK Investigational Site
    Madrid, 28046, Spain
  • GSK Investigational Site
    Banchiau Taipei, 220, Taiwan
  • GSK Investigational Site
    Kaohsiung City, 813, Taiwan
  • GSK Investigational Site
    Bristol Avon, BS10 5NB, United Kingdom
  • GSK Investigational Site
    London, E1 1BB, United Kingdom
  • GSK Investigational Site
    London, NW3 2QG, United Kingdom
  • GSK Investigational Site
    London, SE5 9RS, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Apr 2027, 31 months after the start.

Of 40 industry-sponsored phase 2 interventional studies under Hepatitis B, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 40. This study's planned 31 months is close to that.

Counting every sponsor, half of 50 studies reached it within 30 months; a quarter within 19 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 5, 2024
First posted
Jul 11, 2024
StartActual
Sep 17, 2024
Primary completionEst.
Apr 22, 2027
CompletionEst.
Apr 22, 2027
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: identifiers, verification date and site details
1 update, last Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Minor edits only
    + 3 other changes: identifiers, verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06497504
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jul 11, 2024
Start date
Sep 17, 2024
Primary completion
Apr 22, 2027 (estimated)
Completion
Apr 22, 2027 (estimated)
Last update
Nov 6, 2026

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bepirovirsen

Start the discussion